1. Obvladajmo sladkorno bolezen v Sloveniji. [cited 2019 Jan 28]. Available from: http://www.nijz.si/sl/obvladajmo-sladkorno-bolezen-v-sloveniji 
2. Grossmann M, Thomas MC, Panagiotopoulos S, Sharpe K, Macisaac RJ, Clarke S, et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab. 2008;93(5):1834-40. https://doi.org/10.1210/jc.2007-2177 https://pubmed.ncbi.nlm.nih.gov/18319314 
3. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27(5):1036-41. https://doi.org/10.2337/diacare.27.5.1036 https://pubmed.ncbi.nlm.nih.gov/15111517 
4. Dandona P, Dhindsa S, Chandel A, Chaudhuri A. Hypogonadotropic hypogonadism in men with type 2 diabetes. Postgrad Med. 2009;121(3):45-51. https://doi.org/10.3810/pgm.2009.05.2001 https://pubmed.ncbi.nlm.nih.gov/19491539 
5. Grossmann M. Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab. 2011;96(8):2341-53. https://doi.org/10.1210/jc.2011-0118 https://pubmed.ncbi.nlm.nih.gov/21646372 
6. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93(1):68-75. https://doi.org/10.1210/jc.2007-1792 https://pubmed.ncbi.nlm.nih.gov/17911176 
7. Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS. Low serum testosterone and increased mortality in men with coronary heart disease. Heart. 2010;96(22):1821-5. https://doi.org/10.1136/hrt.2010.195412 https://pubmed.ncbi.nlm.nih.gov/20959649 
8. Holmboe SA, Jensen TK, Linneberg A, Scheike T, Thuesen BH, Skakkebaek NE, et al. Low Testosterone: a risk marker rather than a risk factor for type 2 diabetes. J Clin Endocrinol Metab. 2016;101(8):3180-90. https://doi.org/10.1210/jc.2016-1778 https://pubmed.ncbi.nlm.nih.gov/27285294 
9. Wang C, Nieschlag E, Swerdloff RS, Behre H, Hellstrom WJ, Gooren LJ, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male. 2009;12(1):5-12. https://doi.org/10.1080/13685530802389628 https://pubmed.ncbi.nlm.nih.gov/18763169 
10. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone therapy in men with hypogonadism: an Endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-44. https://doi.org/10.1210/jc.2018-00229 https://pubmed.ncbi.nlm.nih.gov/29562364 
11. Svartberg J, Jenssen T, Sundsfjord J, Jorde R. The associations of endogenous testosterone and sex hormone-binding globulin with glycosylated hemoglobin levels, in community dwelling men. The Tromsø Study. Diabetes Metab. 2004;30(1):29-34. https://doi.org/10.1016/S1262-3636(07)70086-1 https://pubmed.ncbi.nlm.nih.gov/15029095 
12. Jones TH. Testosterone associations with erectile dysfunction, diabetes, and the metabolic syndrome. Eur Urol Suppl. 2007;6(16):847-57. https://doi.org/10.1016/j.eursup.2007.07.002 
13. Cohen PG. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt—a major factor in the genesis of morbid obesity. Med Hypotheses. 1999;52(1):49-51. https://doi.org/10.1054/mehy.1997.0624 https://pubmed.ncbi.nlm.nih.gov/10342671 
14. Dhindsa S, Ghanim H, Batra M, Dandona P. Hypogonadotropic hypogonadism in men with diabesity. Diabetes Care. 2018;41(7):1516-25. https://doi.org/10.2337/dc17-2510 https://pubmed.ncbi.nlm.nih.gov/29934480 
15. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab. 2004;89(2):447-52. https://doi.org/10.1210/jc.2003-031005 https://pubmed.ncbi.nlm.nih.gov/14764746 
16. Guay AT, Bansal S, Heatley GJ. Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: double blind placebo-controlled trial with clomiphene citrate. J Clin Endocrinol Metab. 1995;80(12):3546-52. https://pubmed.ncbi.nlm.nih.gov/8530597 
17. Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med. 1999;130(8):671-80. https://doi.org/10.7326/0003-4819-130-8-199904200-00014 https://pubmed.ncbi.nlm.nih.gov/10215564 
18. Isidori AM, Caprio M, Strollo F, Moretti C, Frajese G, Isidori A, et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab. 1999;84(10):3673-80. https://doi.org/10.1210/jc.84.10.3673 https://pubmed.ncbi.nlm.nih.gov/10523013 
19. Nogueiras R, Barreiro ML, Caminos JE, et al. Novel expression of resistin in rat testis: functional role and regulation by nutritional status and hormonal factors. J Cell Sci. 2004;117(Pt 15):3247-57. https://doi.org/10.1242/jcs.01196 https://pubmed.ncbi.nlm.nih.gov/15226398 
20. Forbes S, Li XF, Kinsey-Jones J, O’Byrne K. Effects of ghrelin on Kisspeptin mRNA expression in the hypothalamic medial preoptic area and pulsatile luteinising hormone secretion in the female rat. Neurosci Lett. 2009;460(2):143-7. https://doi.org/10.1016/j.neulet.2009.05.060 https://pubmed.ncbi.nlm.nih.gov/19477231 
21. Aitken RJ, Roman SD. Antioxidant systems and oxidative stress in the testes. Oxid Med Cell Longev. 2008;1(1):15-24. https://doi.org/10.4161/oxim.1.1.6843 https://pubmed.ncbi.nlm.nih.gov/19794904 
22. Tajar A, Huhtaniemi IT, O’Neill TW, Finn JD, Pye SR, Lee DM, et al.; EMAS Group. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012;97(5):1508-16. https://doi.org/10.1210/jc.2011-2513 https://pubmed.ncbi.nlm.nih.gov/22419720 
23. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR; Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86(2):724-31. https://doi.org/10.1210/jcem.86.2.7219 https://pubmed.ncbi.nlm.nih.gov/11158037 
24. Kumar P, Kumar N, Thakur DS, Patidar A. Male hypogonadism: symptoms and treatment. J Adv Pharm Technol Res. 2010;1(3):297-301. https://doi.org/10.4103/0110-5558.72420 https://pubmed.ncbi.nlm.nih.gov/22247861 
25. Wu FC. Commentary: Guideline for male testosterone therapy: a European perspective. J Clin Endocrinol Metab. 2007;92(2):418-9. https://doi.org/10.1210/jc.2006-2799 https://pubmed.ncbi.nlm.nih.gov/17284643 
26. Grossmann M, Matsumoto AM. A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management. J Clin Endocrinol Metab. 2017;102(3):1067-75. https://pubmed.ncbi.nlm.nih.gov/28359097 
27. Corona G, Rastrelli G, Monami M, Saad F, Luconi M, Lucchese M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013;168(6):829-43. https://doi.org/10.1530/EJE-12-0955 https://pubmed.ncbi.nlm.nih.gov/23482592 
28. Camacho EM, Huhtaniemi IT, O’Neill TW, Finn JD, Pye SR, Lee DM, et al.; EMAS Group. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol. 2013;168(3):445-55. https://doi.org/10.1530/EJE-12-0890 https://pubmed.ncbi.nlm.nih.gov/23425925 
29. Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165(5):675-85. https://doi.org/10.1530/EJE-11-0221 https://pubmed.ncbi.nlm.nih.gov/21753068 
30. Haider A, Saad F, Doros G, Gooren L. Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study. Obes Res Clin Pract. 2014;8(4):e339-49. https://doi.org/10.1016/j.orcp.2013.10.005 https://pubmed.ncbi.nlm.nih.gov/25091355 
31. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009;30(6):726-33. https://doi.org/10.2164/jandrol.108.007005 https://pubmed.ncbi.nlm.nih.gov/19578132 
32. Košnik M, Mrevlje F, Štajer D, Černelč P, Koželj M, Andoljšek D, et al. Interna medicina. 4th ed. Ljubljana: Littera picta; Slovensko medicinsko društvo; 2011. pp. 983-47. 
33. Morgentaler A, Dobs AS, Kaufman JM, Miner MM, Shabsigh R, Swerdloff RS, et al. Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study. J Urol. 2008;180(6):2307-13. https://doi.org/10.1016/j.juro.2008.08.126 https://pubmed.ncbi.nlm.nih.gov/18930255 
34. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899-906. https://doi.org/10.1530/eje.1.02166 https://pubmed.ncbi.nlm.nih.gov/16728551 
35. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, et al.; TIMES2 Investigators. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34(4):828-37. https://doi.org/10.2337/dc10-1233 https://pubmed.ncbi.nlm.nih.gov/21386088 
36. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P; BLAST Study Group. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med. 2014;11(3):840-56. https://doi.org/10.1111/jsm.12404 https://pubmed.ncbi.nlm.nih.gov/24308723 
37. Dhindsa S, Ghanim H, Batra M, Kuhadiya ND, Abuaysheh S, Sandhu S, et al. Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes. Diabetes Care. 2016;39(1):82-91. https://doi.org/10.2337/dc15-1518 https://pubmed.ncbi.nlm.nih.gov/26622051 
38. Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res. 2008;20(4):378-87. https://doi.org/10.1038/ijir.2008.19 https://pubmed.ncbi.nlm.nih.gov/18480825 
39. Mazo EB, Gamidov SI, Sotnikova EM. [Effects of different treatments on endothelial function in patients with erectile dysfunction and hypogonadism]. Ter Arkh. 2008;80(12):59-63. https://pubmed.ncbi.nlm.nih.gov/19227909 
40. Ng Tang Fui M, Prendergast LA, Dupuis P, Raval M, Strauss BJ, Zajac JD, et al. Effects of testosterone treatment on body fat and lean mass in obese men on a hypocaloric diet: a randomised controlled trial. BMC Med. 2016;14(1):153. https://doi.org/10.1186/s12916-016-0700-9 https://pubmed.ncbi.nlm.nih.gov/27716209 
41. Blouin K, Boivin A, Tchernof A. Androgens and body fat distribution. J Steroid Biochem Mol Bio. 2008;108(3-5):272-80. https://doi.org/10.1016/j.jsbmb.2007.09.001 https://pubmed.ncbi.nlm.nih.gov/17945484 
42. Yassin A, Haider A, Haider KS, Caliber M, Doros G, Saad F, et al. Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes: eight-year data from a registry study. Diabetes Care. 2019;42(6):1104-11. https://doi.org/10.2337/dc18-2388 https://pubmed.ncbi.nlm.nih.gov/30862651 
43. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006;91(11):4335-43. https://doi.org/10.1210/jc.2006-0401 https://pubmed.ncbi.nlm.nih.gov/16926258 
44. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60(7):762-9. https://doi.org/10.1111/j.1742-1241.2006.00992.x https://pubmed.ncbi.nlm.nih.gov/16846397 
45. Professional practice committee. Standards of medical care in diabetes—2018. Diabetes Care. 2018;41(1):S3-3. https://pubmed.ncbi.nlm.nih.gov/29222370 
